Ziihera® Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses
Modeyso Included in National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma
Auto Finance Veteran and Former Tesla National Lease Partner Launches AmeriTrust Financial to Fill Used-Car Leasing Gap
Tartisan Nickel Corp. Intersects 10.7 Metres of 1.58% Ni, 0.79% Cu Including 5.0 Metres of 3.02% Ni, 1.48% Cu at the Kenbridge Nickel-Copper-Cobalt Project, Northwestern Ontario
Nextech3D.ai's Krafty Lab Signs New Multinational "Tier 1" Enterprise Agreement and Expands Global In-Person Enterprise Event Delivery
Cartier Discovers Multiple Shallow High-Grade Gold Zones at Cadillac; Cuts 54.6 g/t Au over 1.0 m and 4.4 g/t Au over 6.0 m; Extends North Contact Zone 500 Meters East on Strike
